---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-000419"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T06:41:38.089693+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aldeyra posts FY2022 net loss $62.0M, cash $174.3M; two NDAs under FDA review with PDUFA dates June and Nov 2023

## Summary
- Net loss $62.0M ($1.06/share) vs $57.8M ($1.07/share) in 2021; R&D $47.3M, G&A $15.4M.
- Cash $174.3M at Dec 31, 2022; runway into H2 2024, covering launch preparations if approved.
- FDA Priority Review for ADX-2191 (vitreoretinal lymphoma) with PDUFA June 21, 2023; no filing issues identified.
- FDA accepted NDA for reproxalap (dry eye disease) with PDUFA Nov 23, 2023; no advisory committee planned.
- Upcoming: Phase 3 INVIGORATE-2 allergic conjunctivitis, Phase 2 ADX-2191 RP, Phase 2 ADX-629 cough results expected H1 2023.

## SEC filing metadata
- accession: 0001157523-23-000419
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000115752323000419/0001157523-23-000419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000115752323000419/a53358602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-000419
- JSON: https://secwatch.observer/filing/0001157523-23-000419.json
- Plain text: https://secwatch.observer/filing/0001157523-23-000419.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.